121 related articles for article (PubMed ID: 7472845)
1. Bone mineral density during treatment of central precocious puberty.
Neely EK; Bachrach LK; Hintz RL; Habiby RL; Slemenda CW; Feezle L; Pescovitz OH
J Pediatr; 1995 Nov; 127(5):819-22. PubMed ID: 7472845
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
Boot AM; De Muinck Keizer-Schrama S; Pols HA; Krenning EP; Drop SL
J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy.
van der Sluis IM; Boot AM; Krenning EP; Drop SL; de Muinck Keizer-Schrama SM
J Clin Endocrinol Metab; 2002 Feb; 87(2):506-12. PubMed ID: 11836277
[TBL] [Abstract][Full Text] [Related]
4. Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.
Kapteijns-van Kordelaar S; Noordam K; Otten B; van den Bergh J
Eur J Pediatr; 2003 Nov; 162(11):776-80. PubMed ID: 13680381
[TBL] [Abstract][Full Text] [Related]
5. Effects on bone mineral density of gonadotropin releasing hormone analogs used in the treatment of central precocious puberty.
Unal O; Berberoğlu M; Evliyaoğlu O; Adiyaman P; Aycan Z; Ocal G
J Pediatr Endocrinol Metab; 2003 Mar; 16(3):407-11. PubMed ID: 12705366
[TBL] [Abstract][Full Text] [Related]
6. Changes in bone mineral density and body composition in children with central precocious puberty and early puberty before and after one year of treatment with GnRH agonist.
Ko JH; Lee HS; Lim JS; Kim SM; Hwang JS
Horm Res Paediatr; 2011; 75(3):174-9. PubMed ID: 20881364
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of bone density in girls with precocious and early puberty during treatment with GnRH agonist.
Assa A; Weiss M; Aharoni D; Mor A; Rachmiel M; Bistritzer T
J Pediatr Endocrinol Metab; 2011; 24(7-8):505-10. PubMed ID: 21932589
[TBL] [Abstract][Full Text] [Related]
8. Bone loss during gonadotropin-releasing hormone agonist treatment in girls with true precocious puberty is not due to an impairment of calcitonin secretion.
Saggese G; Bertelloni S; Baroncelli GI; Pardi D; Cinquanta L
J Endocrinol Invest; 1991 Mar; 14(3):231-6. PubMed ID: 1830057
[TBL] [Abstract][Full Text] [Related]
9. Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty.
Saggese G; Bertelloni S; Baroncelli GI; Battini R; Franchi G
Eur J Pediatr; 1993 Sep; 152(9):717-20. PubMed ID: 8223799
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density and body composition in girls with idiopathic central precocious puberty before and after treatment with a gonadotropin-releasing hormone agonist.
Alessandri SB; Pereira Fde A; Villela RA; Antonini SR; Elias PC; Martinelli CE; Castro Md; Moreira AC; Paula FJ
Clinics (Sao Paulo); 2012; 67(6):591-6. PubMed ID: 22760897
[TBL] [Abstract][Full Text] [Related]
11. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty.
Park HK; Lee HS; Ko JH; Hwang IT; Lim JS; Hwang JS
Clin Endocrinol (Oxf); 2012 Nov; 77(5):743-8. PubMed ID: 22530679
[TBL] [Abstract][Full Text] [Related]
12. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty].
Ságodi L; Sólyom E; Lombay B; Almási A; Vámosi I
Orv Hetil; 2012 Mar; 153(11):418-24. PubMed ID: 22390866
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function.
Heger S; Partsch CJ; Sippell WG
J Clin Endocrinol Metab; 1999 Dec; 84(12):4583-90. PubMed ID: 10599723
[TBL] [Abstract][Full Text] [Related]
14. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
[TBL] [Abstract][Full Text] [Related]
15. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
[TBL] [Abstract][Full Text] [Related]
16. Use of a Gonadotropin-releasing Hormone Analog to Treat Idiopathic Central Precocious Puberty Is Not Associated with Changes in Bone Structure in Postmenarchal Adolescents.
Iannetta R; Melo AS; Iannetta O; Marchini JS; Paula FJ; Martinelli CE; Rosa e Silva AC; Ferriani RA; Martins WP; Reis RM
J Pediatr Adolesc Gynecol; 2015 Oct; 28(5):304-8. PubMed ID: 26081481
[TBL] [Abstract][Full Text] [Related]
17. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation.
Antoniazzi F; Zamboni G; Bertoldo F; Lauriola S; Mengarda F; Pietrobelli A; Tatò L
J Clin Endocrinol Metab; 2003 Mar; 88(3):1096-101. PubMed ID: 12629090
[TBL] [Abstract][Full Text] [Related]
18. Bone mineral content in girls with precocious puberty treated with gonadotropin-releasing hormone analog.
Verrotti A; Chiarelli F; Montanaro AF; Morgese G
Gynecol Endocrinol; 1995 Dec; 9(4):277-81. PubMed ID: 8629454
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness of Leuprolide acetate therapy every three months in central precocious puberty].
Mericq G MV; Youlton R R; Willshaw Z ME
Rev Med Chil; 2006 Jul; 134(7):821-6. PubMed ID: 17130963
[TBL] [Abstract][Full Text] [Related]
20. The effect of GnRH analogue treatment on bone mineral density in young adolescents with gender dysphoria: findings from a large national cohort.
Joseph T; Ting J; Butler G
J Pediatr Endocrinol Metab; 2019 Oct; 32(10):1077-1081. PubMed ID: 31472062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
